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Summary
Objective: To develop a Western blot method for quantiﬁcation of multiple aggrecan fragments in human synovial ﬂuids (SFs).
Method: SF aggrecan fragments were prepared from knee healthy (reference), knee injury and arthritis subjects by CsCl gradient centrifuga-
tions collecting D1 fractions. Samples were analyzed by Western blot, using antibodies against the N-terminal epitope ARGS and the G3
domain, and fragments were quantiﬁed using a digital luminescence image analyzer.
Results: The method had a coefﬁcients of variation of 10e30%, and a high correlation (rS¼ 0.86) with a corresponding enzyme-linked immu-
nosorbent assay (ELISA). The SFs from reference, knee injured and arthritic subjects contained two major ARGS fragments, ARGS-SELE and
ARGS-CS1, and three major G3 fragments (GRGT-G3, GLGS-G3 and AGEG-G3). Compared to the reference, the acute arthritis and acute
joint injury groups had a 30-fold elevated concentration of ARGS fragments, and both groups had a higher proportion of the aggrecan in joint
ﬂuid as ARGS fragments compared to the other groups. The reference and chronic injury groups had an excess of ARGS-CS1 fragments over
ARGS-SELE fragments, while subjects with acute arthritis or osteoarthritis had a more even distribution between these fragments.
Conclusions: We have developed a novel Western blot quantiﬁcation method for quantiﬁcation of SF aggrecan fragments which can differen-
tiate fragments of different sizes sharing the same epitope. The anti-ARGS and anti-G3 quantitative Western blots provided information im-
portant for a better understanding of the proteolytic pathways in aggrecan breakdown, information that discriminates between different joint
diseases, and may aid in identiﬁcation of new biomarkers.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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A central feature of arthritis and joint injury is the degrada-
tion of articular cartilage matrix, involving an early loss of
aggrecan fragments into synovial ﬂuid (SF)1e3. Although
both cathepsins4e6 and calpains7,8 cleave aggrecan, the
main proteinases responsible for aggrecan degradation
are the aggrecanases and matrix metalloproteinases
(MMPs)9. The involvement of aggrecanases in human ar-
thritis was ﬁrst shown by the detection of aggrecan frag-
ments with N-terminal sequence 393ARGSb in SF10,11.
Aggrecanases cleave aggrecan in the inter-globular
domain (IGD) at TEGE392Y393ARGS and in the chondroitin
sulfate 2 (CS2) domain at SELE1564Y1565GRGT,
KEEE1733Y1734GLGS, TAQE1838Y1839AGEG and
ISQE1938Y1939LGQR sites12,13. For MMPs, proteolysis at
the IPEN360Y361FFGV site within the IGD is predomi-
nant14e17. An important role of the aggrecanase activity in
aggrecan degradation in joint disease is established, butaThese authors contributed equally to the work.
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497the relative contributions of aggrecanase and other proteo-
lytic activities remain to be deﬁned for different human joint
diseases and disease stages18,19. Animal models have
conﬁrmed the role of aggrecanases in joint cartilage de-
struction in arthritis, but pointed to a possible role for as
yet unidentiﬁed proteolytic activities and species differen-
ces20e26. In the continued work towards a better under-
standing of cartilage destruction in arthritis, and of the
consequences of inhibiting proteolytic pathways as a means
of treating human joint diseases, methods are needed that
in detail map aggrecan fragment patterns in multiple sam-
ples from in vitro, animal models or humans.
We have developed a method that combines small scale
CsCl density gradient centrifugation with quantitative West-
ern blotting, using antibodies speciﬁc for aggrecan proteo-
lytic fragments and domains. It allows a detailed mapping
and quantiﬁcation of aggrecan fragments in multiple sam-
ples of human SF. In contrast to ELISA, fragments of differ-
ent sizes sharing the epitope of detection can be quantiﬁed.Materials and methodsMATERIALSRegular chemicals as described previously19. Human recombinant
ADAMTS-4 (a disintegrin and metalloproteinase with thrombospondin motifs,
aggrecanase-1)27, anti-ARGSVILTVK monoclonal neoepitope antibody (mab
OA-1)28 and anti-AGEGPSGI polyclonal neoepitope antibody were provided
by M. Pratta (GlaxoSmithKline, Collegeville). Quick-Seal centrifuge tubes
(2 ml no. 344625, 12.5 ml no. 342413), tube sealer (no. 342428), tube slicer
(no. 303811) were obtained from Beckman Coulter.
498 A. Struglics et al.: Western blot quantiﬁcation of aggrecanHUMAN SF SAMPLESA pool of knee SF from 47 patients with end-stage knee osteoarthritis
(OA) or with varying stages of post-injury cartilage changes was made
(OA pool control sample). Knee SF was collected from 24 patients with joint
injury or different types of joint disease and four knee healthy individuals
(Table I). Samples were stored at 80C after a brief centrifugation at
3000 g. All procedures were approved by the ethics review committee of
the Medical Faculty of Lund University.AGGRECAN ISOLATION FROM SFNormal D1 preparation (500e800 mg glycosaminoglycan)19 was made
from the SF OA pool. Mini SF-D1 preparation was made from subjects
and from the OA pool: SF was cleared by centrifugation19 and loaded
(30e90 mg glycosaminoglycan/subject) in 2 ml Quick-Seal tubes in the pres-
ence of buffer and proteinase inhibitors (ﬁnal approximate concentrations:
3.5 M guanidinium chloride, 3.1 M CsCl, 52 mM Na-acetate, 10 mM EDTA,
0.41 mM AEBSF, 1.0 mM Pepstatin A, 5.2 mM E64), and fractionated by dis-
sociative CsCl density gradient centrifugation (TLA-120.2 rotor; Beckman
Coulter) at 162,000 g for 72 h at 16C with starting density 1.44 g/ml.
The D1 fractions were collected from the lower half of the tubes at the density
of 1.46e1.54 g/ml and dialyzed against Millipore puriﬁed HPLC-grade water
containing proteinase inhibitors (0.8 mM EDTA, 0.4 mM PMSF, 1 mM
Pepstatin A, 20 mM iodoacetamide, 2 mM o-phenanthroline). Protein (BCA
method) and glycosaminoglycan (Alcian Blue method) content was
measured19 in the SF and D1 samples.WESTERN BLOT ANALYSISDeglycosylated D1 samples (2e4 mg glycosaminoglycan) and ARGS
standards (0.5e3.5 mg glycosaminoglycan) were denatured, reduced19,
and separated according to manufacturer’s instructions by SDS-PAGE
on 3e8% Triseacetate mini-gels (15 wells/gel). Immuno-reactions on polyvi-
nylidene diﬂuoride (PVDF) membranes were done as described19, usingTable
Characteristics of the subjects providing samples for this study. Twenty-
years. M¼male; F¼ female. The joint structure score (OA score) was bas
viously45. A score of 1 represents a joint with no arthroscopic or radiograp
tilage changes, and scores 6e10 increasing radiographic changes consi
injury and joint fluid sample aspiration was 0e2 weeks for the acute in
(AI), 1e11 years for chronic joint injury (CI), and 2 weeks
Sample number Age/sex Diagnosis groups
R1 24/M Reference (R) Health
R2 21/M
R3 51/M
R4 48/M
AA2 30/F Acute inﬂammatory arthritis (AA) Reacti
AA3 49/F Rheum
AA4 66/M Pyroph
AA5 65/M Pyroph
AA6 67/M Pyroph
AA7 57/M Pyroph
AA8 68/M Pyroph
AI1 41/M Acute joint injury (AI) Poster
AI3 35/M Anterio
AI5 30/M Anterio
AI6 39/M Latera
AI7 34/M Media
AI8 39/M Media
AI9 37/M Media
CI1 32/M Chronic joint injury (CI) Anterio
CI2 38/M Anterio
CI3 42/M Media
CI4 42/M Media
CI5 48/M Latera
CI6 46/M Media
OA1 61/F Osteoarthritis (OA) Primar
OA2 41/F Primar
OA3 70/F Primar
OA4 61/M Primaranti-ARGS neoepitope (5.3 mg/ml) or anti-G3 domain (2 mg/ml) antibodies
(Afﬁnity BioReagents; Golden, CO, USA) together with peroxidase-
conjugated secondary antibodies of goat anti-mouse IgG (20 ng/ml) or
goat anti-rabbit IgG (13.3 ng/ml). The immuno-bands were visualized using
either ECL Plus (Amersham Biosciences) or ECL SuperSignal (Pierce)
with the luminescence image analyzer. Speciﬁcity of the anti-ARGS
antibody was conﬁrmed19,28. Speciﬁcity of the G3 antibody was conﬁrmed
by blocking of the immuno-reaction using the immunogen peptide
CDGHPMQFENWRPNQPDN (results not shown).QUANTIFICATION OF AGGRECAN ARGS AND G3 FRAGMENTSComplete conversion of glycosaminoglycan-containing G1 fragments to
ARGS fragments (with corresponding G1-TEGE fragments) was achieved
by digesting 0.5 mg dry weight (333 pmol, Mw of 1.5 106 g/mol) human
cartilage A1D1 fraction19 with 0.5 mg recombinant human ADAMTS-4
(8 pmol, 62.5 kDa as Mw) in buffer (50 mM TriseHCl, 100 mM NaCl,
10 mM CaCl2, pH 7.5) for 24 h at 37
C. The enzymatic reaction (0.5 ml)
was stopped by addition of EDTA (12 mmol) and deglycosylated19. The
digest was assessed for complete conversion by Western blot using
antibodies against the G1, TEGE and ARGS epitopes. The ADAMTS-4
digested and deglycosylated cartilage A1D1 sample was used as ARGS
standard in the Western blot quantiﬁcation, assuming 0.667 nmol ARGS
fragments per milligram aggrecan dry weight and aggrecan molecular
weight of 1.5 106 g/mol (i.e., total protein sequence plus glycosaminogly-
can). Since no G3 standards were available, the SF D1 OA pool was
used as a control for the quantiﬁcation of G3 fragments, expressing the
data as relative units of the control sample. SF D1 samples (from subjects
and OA pool) and ARGS standards (three different concentrations/gel) were
separated by electrophoresis and transferred to PVDF membranes, and
then probed with ARGS or G3 antibodies. Detection and quantiﬁcation of
the ARGS and G3 signals from subjects, control and standard samples
was conducted in luminescence image analyzer (Fujiﬁlm LAS-1000) in the
linear range of the imaging system. The positioning and analysis of regions
of interest of individual bands was done using Fujiﬁlm software Image
Gauge version 4.0.I
eight individuals provided SF samples. Subject age is indicated in
ed on arthroscopic and radiographic assessment as described pre-
hic abnormality, scores 2e5 increasing severity of arthroscopic car-
stent with osteoarthritis (OA). Time between first diagnosis or joint
flammatory arthritis (AA) group, 1e8 weeks for acute joint injury
to 1 year for OA. Nd, not done. Na, not applicable
Clinical diagnosis OA score
y knee Nd
Nd
Nd
Nd
ve arthritis Na
atoid arthritis Na
osphate crystal arthritis 1
osphate crystal arthritis 1
osphate crystal arthritis 1
osphate crystal arthritisþOA 8
osphate crystal arthritis 1
ior crucial ligament tear 1
r crucial ligament tearþmedial meniscus tear 1
r crucial ligament tear þ medial meniscus tear 2
l meniscus tear 1
l meniscus tear 1
l meniscus tear 1
l meniscus tear 4
r crucial ligament tearþ lateral meniscus tear 1
r crucial ligament tearþ lateral/medial meniscus tear 2
l meniscus tear 1
l meniscus tear 2
l meniscus tearþOA 3
l meniscus tear 2
y OA 7
y OA 2
y OA 7
y OA 6
499Osteoarthritis and Cartilage Vol. 17, No. 4The clinical diagnoses of the subjects providing SF samples were kept
blinded during the SF D1 preparations and Western blot analysis. When
summarizing the data, the subjects were grouped according to their clinical
diagnosis (Table I).STATISTICSKruskaleWallis one-way analysis of variance on ranks was used to avoid
mass signiﬁcance due to multiple group comparisons. If signiﬁcances were
found, then ManneWhitney rank sum tests for analysis of unmatched pairs
was run. For correlation analysis, Spearman rank order correlation (rS)
was used. P values< 0.05 were considered signiﬁcant.ResultsMINI-D1 PREPARATION AND WESTERN BLOT SCREENING
METHODLoading the 2 ml CsCl gradient with >20 mg glycosamino-
glycan from the OA pool sample resulted in a glycosamino-
glycan recovery in the D1 fraction of on average 75%
(SD¼ 7, n¼ 9), and recoveries for individual samples
were similar. The puriﬁcation of glycosaminoglycan contain-
ing aggrecan fragments in the D1 sample (measured as
glycosaminoglycan/total protein) was for the OA pool on
average 1250 (SD¼ 119, n¼ 7). When analyzed by
Western blot, there were no qualitative or quantitative differ-
ences of aggrecan fragment patterns between normal and
mini-D1 preparations (results not shown). As a control of
the Western blot quantiﬁcation method, ARGS Western
blot data of SF D1 samples were compared to neat SF sam-
ples from the same subjects with a keratan sulfate (KS)
capture ARGS ELISA28. There was a strong correlation
(rS¼ 0.86, n¼ 18) between results obtained with the
Western blot and ELISA quantiﬁcation methods (Fig. 1).
The Western blot method gave on average 44%
(SD¼ 23, n¼ 18) of the molar values obtained with the
ELISA method.Western blot
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Fig. 1. Correlation between Western blot and ELISA methods in
quantiﬁcation of ARGS fragments. Neat SF from 18 subjects was
analyzed by ARGS ELISA as described28. D1 samples from the
same subjects were quantiﬁed by anti-ARGS Western blot. The
mean values of the total ARGS concentrations (pmol ARGS/ml
SF) are plotted as circles. Solid line shows the ﬁrst order regres-
sion, and broken lines show the 95% conﬁdence intervals. The
Spearman rank order correlation between the Western blot and
ELISA ARGS concentrations was 0.86 and the P value was
<0.0001. Note the logarithmic scales.Coefﬁcients of variation (CV) for the Western blot screen-
ing method were calculated by measuring the total ARGS
signal from the OA pool. Analyses of the OA pool from a sin-
gle D1 preparation showed intra- (n¼ 5) and inter- (n¼ 5)
Western blot assay CV of 11% and 16%, respectively, while
the intra- and inter-Western blot CV between different D1
preparations (n¼ 10) were both about 30%. The intra-
operator CV for applying regions of interest in the image
software around the same lane of total ARGS signal was
1% (n¼ 5).QUALITATIVE WESTERN BLOT ANALYSIS OF ARGS
FRAGMENTSAggrecan fragments were puriﬁed from SF of 28 individ-
uals (Table I) and from the OA pool using the D1 mini-prep
method. The D1 samples were separated by SDS-PAGE
and probed for ARGS fragments using Western blot
(Fig. 2). The SF samples contained two ARGS fragment
regions termed A and B [Fig. 2(A)]. The ARGS region A
(Mw¼ 280e320 kDa) contained a 310 kDa ARGS fragment
which was detected in all subjects [band a2; Fig. 2(B)], iden-
tiﬁed previously as a 393ARGS-SELE1564 fragment19. The
ARGS standard and the subjects in the acute arthritis group
had an additional 288 kDa ARGS fragment located in region
A [band a3 in Fig. 2(B)], while this fragment was missing in
the other subject groups. The 288 kDa ARGS fragment had
an estimated (using a calculation model29) C-terminal of
-GTLG1500 in the CS1 domain, suggesting that the C-
terminal was generated by m-calpain cleavage8 at
EDLS1472Y1473GLPS, corresponding to a 393ARGS-
EDLS1472 polypeptide. A 367 kDa ARGS fragment [band
a1; Fig. 2(B)], had an estimated (using the calculation
model29) C-terminal of -TQAP1834 in the CS2 domain, sug-
gesting that it was generated by aggrecanase cleavage at
TAQE1838Y1839AGEG and therefore corresponded to
a 393ARGS-TAQE1838 polypeptide. This fragment was
detected in some of the acute joint injury (AI) subjects
(e.g., AI1 and AI8). The broad ARGS-reactive region B
(Mw¼ 120e160 kDa) corresponded to multiple 393ARGS-
CS1 fragments where the C-terminal was estimated29 to
-GV(G/E)D952e1409, suggesting several MMP cuts in the
CS1 region14. The anti-ARGS antibody (mab OA-1) showed
a similar immuno-pattern in Western blots as the commer-
cially available anti-ARGS antibody BC-3 (results not
shown).QUALITATIVE WESTERN BLOT ANALYSIS OF G3 FRAGMENTSD1 samples were separated by SDS-PAGE and probed
for G3 fragments using Western blot (Fig. 3). The majority
of the SF samples contained three dominant G3 fragments:
band a (214 kDa), b (171 kDa) and c (137 kDa) (Fig. 3).
Fragment c was identiﬁed as 1839AGEG-G3 by Western
blot using anti-AGEG and anti-G3 antibodies (result not
shown); fragments a and b were estimated by the calcula-
tion model29 as putative 1565GRGT-G3 and 1734GLGS-G3
fragments, respectively. A weakly reactive G3 fragment,
band d (103 kDa), was present in some of the samples
(e.g., CI1 and CI2; Fig. 3). This fragment was identiﬁed by
Western blot as 1939LGQR-G3 using anti-LGQR and anti-
G3 antibodies (our results not shown; Sandy and Verscha-
ren30). A G3 fragment, band e (68 kDa), was present in
several acute and chronic injury (CI) samples (e.g., AI7,
AI8, CI3 and CI4) and in the reference sample R1
(Fig. 3). The N-terminal of fragment e was estimated by
the calculation29 as a sequence starting with 2074PTAS,
CI1 8 9 5
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Fig. 2. Anti-ARGS Western blots of SF samples. SF D1 samples from subjects (2 or 4 mg glycosaminoglycan) and from the OA pool (2 mg
glycosaminoglycan), and ARGS standards (Std 1e3; 0.5, 1.5 and 3.5 mg glycosaminoglycan) were separated on four SDS-PAGE gels and
transferred to PVDF membranes (IeIV). Each of the gels contained the ARGS standards and the OA pool (only shown for membrane I).
The membranes were probed by the anti-ARGS antibody and the signal was captured by the luminescence image analyzer. Region A
(280e320 kDa) contains two high-Mw ARGS fragments of 288 and 310 kDa. Region B (120e160 kDa) contains multiple ARGS fragments.
The position of Mw markers (in kDa) is indicated. (B), an enlargement from (A), shows ARGS polypeptides a3 (288 kDa) and a2
(310 kDa) located in region A, and ARGS polypeptide a1 (367 kDa). Membranes IeIII were from one experiment, and membrane IV was
from a second Western blot experiment. The images show representative anti-ARGS signals from full size blotted gels. Groups (see also
Table I): R (R1e4); AA (AA2e8), AI (AI1, 3, 5e9), CI (CI1e6) and OA (OA1e4).
500 A. Struglics et al.: Western blot quantiﬁcation of aggrecanlocated approximately 90 amino acids upstream from the
end of the CS2 domain.
The G3 fragments aed were also detected in the OA pool
SF sample and were present in aggrecanase in vitro di-
gested human A1D1 cartilage samples (not shown). In ad-
dition to the G3 fragments aee, several of the samples also
contained high Mw G3 fragments marked region A
(370e445 kDa) and B (280e335 kDa) representing G3
fragments with unidentiﬁed N-terminals. Their high Mw sug-
gests that some of these polypeptides are full length aggre-
can (Fig. 3). Notably, subject OA1 lacked G3 fragments
aee, only containing minor quantities of G3 fragments in re-
gion B (Fig. 3).QUANTITATIVE WESTERN BLOT ANALYSIS OF ARGS
FRAGMENTSFor Western blot quantiﬁcation of ARGS fragments each
membrane, containing a subset of individual samples, was
loaded with three different concentrations of ARGS stan-
dards and the OA pool as a control. After subtracting the
background signal, an average arbitrary unit (AU)/mol
ARGS fragment was calculated from three standard con-
centrations on each membrane, and used for the calculationof the ARGS concentration in the samples. Average ARGS
concentrations for each subject sample were calculated
from 2e5 separate Western blot experiments, and the over-
all CV for the 28 subjects was 21%. The linear range of the
ARGS standards in the luminescence image system was
0.25e6 mg glycosaminoglycan (R2¼ 0.99), and the ARGS
signal of the subject samples was analyzed within this AU
range (results not shown).
As shown for aggrecan31, there was an individual varia-
tion of aggrecan and ARGS concentrations within the diag-
nostic groups [Table II, Fig. 2(A)]. Comparing group
medians showed that the AA and AI groups had the highest
total ARGS concentrations, 34- and 38-fold higher than the
reference group, and 15- to 29-fold higher than the median
levels in the OA and CI groups, while there were only minor
non-signiﬁcant differences between the reference, the CI
and the OA groups. (Table II). The concentrations of
ARGS fragments in regions A and B showed only minor dif-
ferences between the reference, CI and OA groups, while
for the AA group higher concentrations of ARGS fragments
were present in both regions A and B compared to the ref-
erence, CI and OA groups [Fig. 4(A,B)].
Comparing the relative distribution of ARGS regions A
and B altered the perspective [Fig. 4(C)]; the OA group
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Fig. 3. Anti-G3 Western blots of SF samples. SF D1 samples (4 mg glycosaminoglycan/well) from subjects and from the OA pool were sep-
arated on four SDS-PAGE gels and transferred to PVDF membranes (IeIV). Each of the gels contained the OA pool (only shown for mem-
brane I). The membranes were probed by the anti-G3 antibody and the signal was captured by the luminescence image analyzer. G3
fragments a (214 kDa), b (171 kDa), c (137 kDa), d (103 kDa) and e (68 kDa), and G3 region A (370e445 kDa) and B (280e335 kDa) and
Mw markers (in kDa) are indicated. Membranes IeIII were from one experiment and membrane IV was from a second Western blot exper-
iment. The images show representative anti-G3 signals from full size blotted gels. Groups (see also Table I): R (R1e4); AA (AA2e8), AI
(AI1, 3, 5e9), CI (CI1e6) and OA (OA1e4).
501Osteoarthritis and Cartilage Vol. 17, No. 4showed a 2-fold higher proportion of region A compared to
the reference, a similar differential was also suggested for
the AA group, without statistical signiﬁcance [Fig. 4(C)].
Overall, the total SF ARGS concentrations correlated
(rS¼ 0.81) with the SF glycosaminoglycan concentrations
determined by Alcian Blue precipitation [Fig. 5(A)]. How-
ever, when comparing the molar proportions of ARGS frag-
ments of aggrecan in the groups, approximately half of the
aggrecan fragments in the AA and AI SFs carried the ARGS
N-terminal sequence, while the corresponding proportions
of ARGS fragments for the other groups were lower (Table
II). For this comparison, an estimation of the molar amounts
of aggrecan in SF was done (Table II) based on sulfated
glycosaminoglycan (sGAG) concentrations assuming that:
(1) Aggrecan is the predominant proteoglycan carrying
sGAG in SF. (2) The average total molecular weight for
the aggrecan molecule in SF is 1.5 106 g/mol and that
75% of this Mw is represented by glycosaminoglycan. For
four individuals, who had more than 40% of the aggrecanTable I
Concentrations of glycosaminoglycan, aggrecan and ARGS fragments in
calculated from sGAG concentrations (Alcian Blue method, see text), and
Western blot. Data expressed as median (minemax range) values in diag
reference group (Norm). P-values, significance analysis (ManneWhitney
(%), estimated proportion as ARGS fragments out of total amount of aggre
ing to Tab
Diagnostic
groups
n sGAG (mg/ml SF) Aggrecan
(pmol/ml SF)
Total ARGS
(pmol/ml SF)
R 4 81 (59e88) 72 (52e78) 2.5 (1.7e5.2)
AA 7 157 (80e425) 140 (71e450) 85.0 (33.3e264.
AI 7 224 (61e728) 251 (54e647) 94.5 (1.1e646.9
CI 6 51 (38e177) 45 (34e246) 3.3 (1.3e62.5)
OA 4 84 (31e179) 74 (28e159) 5.6 (0.6e29.6)as ARGS fragments and the ratio of region A/B was below
1, 1.2 106 g/mol and 60% was used as an estimated
average (this correction changed the median level of the
AI group from 59% to 44%). The molar proportions of
ARGS of aggrecan in the groups were similar when the
amount of aggrecan was estimated from quantiﬁcation of
total aggrecan by ELISA using the monoclonal antibody
1-F21 recognizing a peptide sequence in the keratan sulfate
domain32 (result not shown).QUANTITATIVE WESTERN BLOT ANALYSIS OF G3
FRAGMENTSFor Western blot quantiﬁcation of G3 fragments, each
membrane, containing a subset of subject samples, was
also loaded with the OA pool (Fig. 3). The G3 concentra-
tions of the individual samples, expressed as amount of
G3 (in AU) per milliliter SF, were calculated, and related
to the G3 signal for the OA pool on the same membrane.I
human SFs. Concentrations of total aggrecan in SF subjects were
total ARGS fragment concentrations measured in D1 samples using
nostic groups. Median values of ARGS were normalized against the
) of the AA or AI group vs the rest of the diagnostic groups. ARGS
can estimated from sGAG content. Diagnostic groups were accord-
le I
Norm P-values ARGS (%) P-values
vs AA vs AI vs AA vs AI
1 0.006 0.073 3.9 (2.6e6.7) 0.006 0.109
0) 34.3 e 0.902 54.6 (22.5e84.9) e 0.456
) 38.1 0.902 e 43.6 (2.0e100.0) 0.456 e
1.3 0.008 0.073 8.0 (2.5e25.4) 0.002 0.234
2.3 0.006 0.164 8.5 (2.3e18.6) 0.006 0.315
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Fig. 4. Concentration of ARGS fragments in region A (310 kDa ARGS-SELE and 288 kDa ARGS-CS1 fragments) and region B (120e160 kDa
ARGS-CS1 multiple fragments). ARGS concentrations for fragments in regions A and B were quantiﬁed (using D1 samples) by Western blot
and luminescence image analyzer and the mean concentrations for the regions of each subject were calculated. Median values (circles) and
the twenty-ﬁfth and seventy-ﬁfth percentiles (whiskers) of different diagnostic groups are shown. (A) ARGS concentration in region A. (B)
ARGS concentration in region B. (C) The ratio of the ARGS concentration of region A over region B. Diagnostic groups according to Table
I: R (n¼ 4), AA (n¼ 7), AI (n¼ 7), CI (n¼ 6) and OA (n¼ 4).
502 A. Struglics et al.: Western blot quantiﬁcation of aggrecanDue to high and uneven G3 background signal, consistent
background correction was not possible. Average G3 con-
centrations were calculated from 2e5 Western blot experi-
ments for each subject, and the overall G3 CV for the 28
subjects was 39%. The linear range of the G3 signal in
the luminescence image system was 0.5e8 mg glycosami-
noglycan (R2¼ 0.97) for the OA pool, and the G3 signal
of the subject samples was analyzed within this AU range
(results not shown).
The correlation between the total G3 signal in the subject
samples and the glycosaminoglycan concentrations was
moderate [rS¼ 0.63; Fig. 5(B)]. Results suggested that the
median total G3 signal in the OA diagnostic group was
about one third of that in the reference group, while the
AA group did not differ from the reference group (Table III).
The major G3 fragments a, b and c corresponding to
GRGT-G3, GLGS-G3 and AGEG-G3, respectively, consti-
tuted 76e100% of the total G3 signal on the diagnostic group
level (patient OA1 excluded due to lack of G3 signal) (Fig. 3).
The relative contribution of each of these three G3 fragments
to their sum (percent a of aþ bþ c), ranged from 13e53 per-
cent in the individuals, and their relative order of contribution
varied between diagnostic groups (result not shown).ARGS/G3 FRAGMENT RATIOSThe total ARGS and total G3 concentrations in the sam-
ples, expressed as AU per milliliter SF, were ﬁrst related to
the total ARGS and G3 concentrations in the OA pool sam-
ple, and a ratio between the ARGS and G3 signals in rela-
tive units was then calculated for each sample. The ARGS/
G3 fragment ratio varied between individual subjects, but
with a discernible pattern when comparing diagnostic
groups (Fig. 6). The median ARGS/G3 ratios for the refer-
ence and CI groups were low and did not differ. For the
AA and AI groups, the ARGS/G3 ratios were 19- and10-fold higher than in the reference group, respectively,
while the AA group had an 8-fold higher ratio compared to
the CI group (Fig. 6).Discussion
Several methods have been presented for quantiﬁcation
of proteinase cleaved aggrecan fragments using neoepi-
tope antibodies in an ELISA format24,28,31,33e35. The West-
ern blot quantiﬁcation method presented here allows the
quantitative detection of fragments with the neoepitope
ARGS or with the G3 domain. Importantly, it also discrimi-
nates between different proteolytic fragments carrying the
same epitope, and therefore allows a more detailed quanti-
tative analysis of the products of aggrecan proteolysis than
previously achieved. The method allowed the demonstra-
tion of quantitative as well as qualitative differences in ag-
grecan fragment patterns between SF samples obtained
from patients with different joint diseases.
The qualitative analysis showed that all the subject SF
samples contained ARGS-SELE, the major fragment in re-
gion A, and ARGS-CS1 fragments (the multi-ARGS frag-
ments in region B). Only traces of ARGS fragments with
Mw below 100 kDa were detected in the SF D1 samples
(not shown). Except for the ARGS region A and B frag-
ments, no other ARGS fragments were detected by West-
ern blot amongst aggrecan fragments captured in the
plate wells of the KS capture ARGS ELISA, or in aggrecan
samples puriﬁed from SF by Q-Sepharose anion chroma-
tography (not shown). These results suggest that the
ARGS-SELE and the ARGS-CS1 are the dominating
ARGS fragments in normal, joint injured and arthritic human
SFs. Other groups have described similar high Mw
(>250 kDa) ARGS fragments in SFs30,36,37, but also signif-
icant amounts of low Mw (100e150 kDa) ARGS
fragments36,37.
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Fig. 5. Correlation between sGAG vs ARGS and G3 fragment con-
centrations in SF samples. Total ARGS and G3 fragments were
quantiﬁed from the different subjects and from the OA pool (using
D1 samples) by Western blot and luminescence image analyzer,
and mean concentrations (in amount/ml SF) for each subject
were calculated. The sGAG concentrations were analyzed in neat
SF from the same subjects (n¼ 28) using the Alcian Blue method.
Solid lines show the ﬁrst-order regression, and the broken lines
show the 95% conﬁdence intervals. Spearman rank order correla-
tion was in (A) 0.81 (P< 0.0001), and in (B) 0.63 (P< 0.0001).
Note the logarithmic scales.
Table III
Total G3 concentration in SF samples. G3 concentrations were de-
termined (using D1 samples) by Western blot and luminescence
image analyzer. The mean concentration for each subject (based
on AU/ml SF) was calculated expressed as relative units against
the OA pool sample. Group median values (minemax range) of to-
tal G3 signal, in relative units are shown. Median values normalized
against the reference group (Norm). P-values, significance analysis
(ManneWhitney) of the R group against the rest of the groups.
Diagnostic groups were according to Table I
Diagnostic groups n Total G3 (relative units) Norm P-values
R 4 0.99 (0.53e1.92) 1 e
AA 7 1.06 (0.93e5.47) 1.1 0.527
AI 7 2.83 (0.21e9.98) 2.9 0.163
CI 6 0.67 (0.13e3.16) 0.7 0.476
OA 4 0.28 (0.09e0.53) 0.3 0.057
503Osteoarthritis and Cartilage Vol. 17, No. 4The GRGT-G3, GLGS-G3 and AGEG-G3 N-terminals
generated by aggrecanase cleavages in the CS2 domain
have been identiﬁed by others12,30, with the same Mw
and polypeptide pattern as presented here. These
fragments, and the LGQR-G3 fragment, are not present in
human cartilage A1D1 fraction, but can be generated by
aggrecanase in vitro digestion (results not shown). The
mini D1 fractions had densities of 1.46e1.54 g/ml. This
suggests that also lightly glycosaminoglycan substituted
fragments such as the 103 kDa LGQR-G3 and 68 kDa
PTAS-G3 fragments (with 11 and 4 potential CS chain
substitutions, respectively) migrate to the density of the
D1 fraction. These G3 fragments were also detected by
Western blot in Q-Sepharose puriﬁed SF samples with sim-
ilar intensities as in the SF D1 samples (not shown). Theseresults suggest that the GRGT-G3, GLGS-G3, AGEG-G3,
LGQR-G3 and PTAS-G3 are the dominating G3 fragments
in normal, joint injured and arthritic human SFs.
In the choice of ARGS standard, a complete aggreca-
nase digest of the cartilage A1D1 fraction was found well
suited, since the un-digested fraction does not contain
any G1-TEGE or ARGS fragments19. However, as a stan-
dard for molar quantiﬁcation of G3, the A1D1 fraction pre-
pared from adult human OA cartilage19 is not suitable
since it contains only low amounts of full length monomer
(20% G1eG3) and a major proportion C-terminally trun-
cated fragments (60% G1-SELE/KEEE and 20% G1-CS1)
(our data, not shown). Instead, we used a control sample
(SF D1 OA pool) for the quantiﬁcation of G3 fragments, ex-
pressing the data as relative units of the control sample.
When comparing the ARGS Western blot and ELISA
methods using the same antibody and standard, they
showed a strong linear correlation indicating that total
ARGS fragment content in SF samples by ELISA was re-
ﬂected by analysis of SF D1 samples with the Western
blot method. Although the lower total ARGS values ob-
tained with the Western blot method in part may be due
to losses in the CsCl gradient centrifugation step, no addi-
tional ARGS fragments were detected by Western blot in
aggrecan captured by the KS capture ARGS ELISA (not
shown). Only 18 of the 28 SF samples had detectable
ARGS concentration in the ELISA, and the 10 subjects
(R1-4, OA3, AI7, AI9, CI3, CI4 and CI6) who had non-
detectable ARGS concentration by ELISA also showed
the lowest concentrations by Western blot [Fig. 2(A)].
Both ARGS and G3 signals correlated overall with the
glycosaminoglycan concentration in the SFs. A similar
correlation was observed between the concentration of
the aggrecan neoepitope fragment 361FFGV, generated by
MMP cleavage in the IGD, and glycosaminoglycan concen-
trations in SFs from OA patients33. This is consistent with
previous observations showing that these types of
aggrecan fragments make up a signiﬁcant proportion of
the glycosaminoglycan content in human SF19,24,31,33.
We previously showed increased concentrations of
glycosaminoglycan and different aggrecan epitopes (by
ELISA) in SF samples from patients with OA, acute
pyrophosphate arthritis, and knee injuries, compared with
knee healthy reference subjects31,38. Here we show, by
a fragment speciﬁc quantitative Western blot method,
increased concentrations of the aggrecanase generated ag-
grecan neoepitope ARGS in SF samples from several
different joint diseases, again compared with samples
from knee healthy reference subjects. We estimated the
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Fig. 6. ARGS/G3 ratios in SF samples. The total ARGS and total
G3 fragment concentrations from the subjects and the OA pool
were quantiﬁed (amount/ml SF), using Western blot and lumines-
cence image analyzer, and the mean values were calculated for
each subject. The subjects’ relative ARGS and G3 signals were ﬁrst
calculated against the OA pool, and then divided giving an ARGS/
G3 ratio. Median values (circles) and the twenty-ﬁfth and seventy-
ﬁfth percentiles (whiskers) of different diagnostic groups are shown.
Diagnostic groups according to Table I: R (n¼ 4), AA (n¼ 7), AI
(n¼ 7), CI (n¼ 6) and OA (n¼ 4).
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ARGS standard generated by complete aggrecanase
digestion of human aggrecan, and also estimated the
aggrecan fragment content in SF based on glycosaminogly-
can concentrations. Acknowledging the uncertainties in
these estimates, our results nevertheless suggest that the
diagnostic groups studied here show widely different pro-
portions of the total glycosaminoglycan content of SF de-
tectable as aggrecan ARGS fragments. Interestingly, the
AA and AI groups both showed a high proportion of
glycosaminoglycan in ARGS fragments, while the other
groups contained much lower proportions, suggesting that
a marked release of ARGS fragments into human SF is
associated with a high joint disease activity.
In a further extension of previous knowledge, our obser-
vations suggest an excess of ARGS-CS1 (region B) frag-
ments over ARGS-SELE (region A) fragments in the
reference and CI samples, while the AA and OA samples
showed a more even distribution between these fragments
[Fig. 4(C)]. These results show that determination of glycos-
aminoglycan content only, or even total neoepitope content,
in, e.g., SF provides an incomplete picture of the cartilage
degradation process in human joint disease. Our results
further show that there are only minor differences between
the disease groups in the total G3 fragment signal in the SF
samples. A separate analysis of the three main G3fragments (GRGT-G3, GLGS-G3 and AGEG-G3) sug-
gested variations in the proportions of these fragments be-
tween the diagnostic groups (not shown), demonstrating
again a signiﬁcant complexity in aggrecan degradation.
The sum of the detected ARGS neoepitope carrying frag-
ments reﬂects aggrecanase activity directed against the
IGD domain of aggrecan. The majority of the detected G3
epitope signal derived from fragments with a size consistent
with their N-terminal being located in the aggrecan CS2 do-
main, and the total G3 signal may thus reﬂect aggrecanase
activity against the CS2 domain. Combining these results
into a ratio between ARGS and G3 epitope signals could
thus provide an indication of the relative activity of aggreca-
nase against these two aggrecan domains, and or the rela-
tive substrate availability. Again, our results showing
differences in this particular measure between diagnostic
groups emphasize the diversity of fragments released,
and how improved analytical techniques may be needed
to interpret the physiology and pathology of cartilage matrix
degradation.
The CS2 domain proteolysis is believed to represent
a process of natural aggrecan turnover and aging, while
proteolysis in the IGD, which releases the entire water-
binding part of aggrecan from the extracellular matrix, is
suggested to be a pathological event associated with carti-
lage degradation10,18. Our results showing variable ratios of
ARGS to G3 epitope signals between the diagnostic groups
could thus indicate a high relative level of pathological
aggrecanase degradation activity in the AA, AI and OA
groups, and lower in the reference and CI groups. A similar
aggrecan degradation index based on aggrecan fragment
FFGV/G1eG2 domain ratios was recently reported24.
While the discussion above reﬂects a relatively straight-
forward interpretation of our results, several alternative
interpretations are possible. Firstly, if physiological turnover
and aging involve the gradual C-terminal trimming of aggre-
can molecules in joint cartilage, then the average available
aggrecan substrate may vary with, e.g., the age of the
individual. This would inﬂuence the pattern of fragments
released into the SF following an up-regulated proteolytic
activity, confounding interpretations. Secondly, joint carti-
lage is a major source of aggrecan fragments appearing
in SF, but may not be the sole source; they may also to
a variable extent originate from, e.g., menisci, ligaments
and synovial tissue39e41. The synovial cells of the joint
capsule contain aggrecanase activities42,43. Thirdly, we
have assumed that aggrecan fragments appearing in SF
are the result of proteolysis of resident, functional matrix
molecules. There is evidence for an increased aggrecan
synthesis in OA and after joint injury31. Some of the aggre-
can fragments appearing in SF may therefore be the prod-
uct of aggrecanase activity directed against newly
synthesized aggrecan molecules, not yet fully incorporated
into the matrix44.
This study has some general limitations. (1) An enrich-
ment of aggrecan fragments is necessary before analysis
by SDS-PAGE and Western blot; here we use dissociative
CsCl centrifugation assuming that the proportion of aggre-
can fragments in the D1 fraction reﬂects the in vivo situation
in the SF. (2) Any differences in the afﬁnity of the antibodies
for fragments of different size carrying the same epitope
would affect the detected ratio of the signals. (3) Although
done within the known linear range of both the ARGS and
G3 quantiﬁcation systems, extrapolation from a limited set
of standards (ARGS) or expressing data in relative units
(G3) limits the accuracy of the Western blot quantiﬁcation
method. (4) The average aggrecan substrate structure in
505Osteoarthritis and Cartilage Vol. 17, No. 4joint cartilage may vary with, e.g., age, disease stage and
synthesis rate of new molecules, and the diagnostic groups
were not matched for age. A more extended analysis of
a larger number of patient samples is needed to determine
the inﬂuence of these potential confounders. With the
limited number of samples used, our ability to detect minor
differences between diagnostic groups was limited.
We have developed a novel application of small scale
CsCl gradient centrifugation and Western blot for quantiﬁca-
tion of human SF aggrecan fragments. Combined with anti-
bodies detecting the neoepitope ARGS in the IGD, and the
G3 domain of aggrecan, the method provides new informa-
tion on aggrecan fragment patterns in human SF, as well as
previously unknown differences in the patterns between
groups of patients with different joint diseases. These differ-
ent fragment patterns may reﬂect variations in proteolytic
activity in the joint in different arthritides. The method allows
a detailed mapping of aggrecan fragment patterns in multi-
ple samples from in vitro and in vivo samples, animal
models or humans. This will help determine the relative con-
tributions of aggrecanases and other proteolytic activities in
human joint diseases and disease stages. Such information
is important for a better understanding of cartilage destruc-
tion in arthritis, and of the consequences of inhibiting pro-
teolytic pathways as a means of treating human joint
diseases20e26.Conﬂict of interest
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